Thursday, 5 November 2026European Markets

AVANCE GAS HOLDING Stock 11.19% Up Today

Loading stream...

(VIANEWS) - The Market ended the session with AVANCE GAS HOLDING (AGAS.OL) rising 11.19% to kr192.80 on Wednesday while Oslo Børs Benchmark Index_GI fell 0.56% to kr1,409.06.

AVANCE GAS HOLDING's last close was kr173.40, 68.02% higher than its 52-week high of kr103.20.

About AVANCE GAS HOLDING

Avance Gas Holding Ltd, together with its subsidiaries, engages in the transportation of liquefied petroleum gas (LPG) worldwide. The company transports LPG from the Middle East Gulf and the United States Gulf/the United States East Coast to destinations in Europe, South America, India, and Asia. As of December 31, 2023, it owned and operated through a fleet of fourteen very large gas carriers and six dual-fuel LPG newbuildings. Avance Gas Holding Ltd was founded in 2007 and is based in Hamilton, Bermuda. Avance Gas Holding Ltd is a subsidiary of Hemen Holding Ltd.

Earnings Per Share

As for profitability, AVANCE GAS HOLDING has a trailing twelve months EPS of kr23.01.

PE Ratio

AVANCE GAS HOLDING has a trailing twelve months price to earnings ratio of 8.38. Meaning, the purchaser of the share is investing kr8.38 for every norwegian krone of annual earnings.

Return on Equity

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 17.24%.

Volatility

AVANCE GAS HOLDING's last week, last month's, and last quarter's current intraday variation average was 1.24%, 1.29%, and 2.56%.

AVANCE GAS HOLDING's highest amplitude of average volatility was 1.32% (last week), 2.11% (last month), and 2.56% (last quarter).

More news about AVANCE GAS HOLDING (AGAS.OL).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Oncology Data Season and Biotech Capital Allocation: ESMO Readouts, Ivonescimab PDUFA, and Diverging Corporate Moves
Late-2026 biotech is driven by a dense catalyst calendar. ESMO 2026 delivers data from ivonescimab, Enhertu, R-DXd and bemarituzumab, and the FDA has set a 14 Nov PDUFA date for the ivonescimab BLA. Capital allocation is diverging. Krystal Biotech authorized a $400M buyback while lowering FY2026 spend guidance and pushing milestones into 2027. Spago is moving to delist from Nasdaq First North. The facts are clinical and corporate events, not AI or fintech, so the finance angle is limited to capital markets (buybacks, guidance, delistings, regulatory timelines).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,549 source documents archived
Query this data → isubstrate.com